Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 12/20 | 0.35 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2783200 | 0.84 | VNN1 (0.37) | — | |
| SCHEMBL2784105 | 0.81 | VNN1 (0.35) | — | |
| SCHEMBL2783201 | 0.80 | CKS1B (0.33) | — | |
| SCHEMBL2784108 | 0.75 | CKS1B (0.37) | — | |
| SCHEMBL9290582 | 0.70 | — | — | |
| Hydrochloric Acid SCHEMBL1326989 | 0.69 | — | — | |
| SCHEMBL2781837 | 0.69 | — | — | |
| SCHEMBL2110457 | 0.69 | HCAR3 (0.41) | HCAR3 | |
| SCHEMBL12497152 | 0.67 | MAPK1 (0.68) | MAPK1 | |
| SCHEMBL2112115 | 0.65 | ESR2 (0.43) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115139-B2 | Pyrazinooxazepine derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-25 | — | — | US | disclosed |
| EP-2442870-B1 | PYRAZINOOXAZEPINE DERIVATIVES | TAKEDA PHARMACEUTICAL (JP) | 2014-04-16 | — | — | EP | disclosed |
| US-8324201-B2 | Pyrazinooxazepine derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-04 | — | — | US | disclosed |
| US-8318722-B2 | Pyrazinooxazepine derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-27 | — | — | US | disclosed |
| US-8314088-B2 | Pyrazinooxazepine derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-20 | — | — | US | disclosed |
| US-20120135979-A1 | PYRAZINOOXAZEPINE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-31 | — | — | US | disclosed |
| EP-2442870-A1 | PYRAZINOOXAZEPINE DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2012-04-25 | — | — | EP | disclosed |
| US-20110288291-A1 | PYRAZINOOXAZEPINE DERIVATIVES | SASAKI SHIGEKAZU (JP) | 2011-11-24 | — | — | US | disclosed |
| US-20110282054-A1 | PYRAZINOOXAZEPINE DERIVATIVES | SASAKI SHIGEKAZU (JP) | 2011-11-17 | — | — | US | disclosed |
| WO-2010147226-A1 | PYRAZINOOXAZEPINE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-23 | — | — | WO | disclosed |
| US-20100317651-A1 | PYRAZINOOXAZEPINE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135979-A1 | PYRAZINOOXAZEPINE DERIVATIVES | HTR5A, HTR2C, HTR2A | MAPK1 1602/4885HCAR3 604/4885HSP90AA1 3339/4885 |
| US-20100317651-A1 | PYRAZINOOXAZEPINE DERIVATIVES | HTR2C, HTR5A, HTR2A | MAPK1 1247/4885HCAR3 420/4885HSP90AA1 2899/4885 |
| US-20110288291-A1 | PYRAZINOOXAZEPINE DERIVATIVES | HTR2C, HTR5A, HTR2A | MAPK1 1247/4885HCAR3 420/4885HSP90AA1 2899/4885 |
| US-20110282054-A1 | PYRAZINOOXAZEPINE DERIVATIVES | HTR2C, HTR5A, HTR2A | MAPK1 1247/4885HCAR3 420/4885HSP90AA1 2899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.